Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GENpoll: Dec 13, 2011

OS vs. PFS

Should the primary endpoint for approval of cancer drugs change to progression-free survival from overall survival?

Yes
 
  42.1%
No
 
  42.1%
Undecided
 
  15.8%

Suggest a Poll
« More Polls » « View Results »

FDA’s success in removing Avastin’s metastatic breast cancer (MBC) indication has sparked a longstanding debate in drug development circles: Should the primary endpoint for regulatory sanction remain overall survival (OS) or should it change to progression-free survival (PFS)? In Avastin’s case, initial accelerated approval, in combination with paclitaxel, for MBC was based on PFS data. But last year FDA’s CDER recommended that MBC be withdrawn since subsequent studies showed only a small improvement in OS. FDA also noted that Avastin’s PFS improvement was not worth the risk of associated side effects. Avastin maker Genentech and parent Roche countered that PFS should be the primary endpoint, because it could be objectively measured and because the EU recognized it as an oncology endpoint. Where do you stand?

Related content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

BLOG biotech

MORE RELATED BLOG BIOTECH

Webinars

MORE RELATED WEBINARS

GEN Podcasts

MORE RELATED GEN PODCASTS

Video Channel

MORE RELATED VIDEO CHANNEL

New Products

MORE RELATED NEW PRODUCTS

Best of the Web

MORE RELATED BEST OF THE WEB

GEN Polls

MORE RELATED GEN POLLS

Subscription center

BACK TO TOP

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.
 

All fields are required
Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

GEN webinars

« View All Webinars »

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll
« More »     « View Results »     « Poll Archive »